There are so many arguments against NWBO's Phase 3 trial. The evidence is questionable with post hoc trial redesign, data dredged recurrent GBM, confounded OS data questions validity, still unanswered recruiting issues that stopped the trial, etc.
It will be had to see regulators buying such dubious trial.
Market Data 
Markets 
AI
